Karyopharm Therapeutics Target of Unusually High Options Trading (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of some unusual options trading on Thursday. Traders acquired 10,965 call options on the company. This represents an increase of 817% compared to the typical volume of 1,196 call options.

Wall Street Analyst Weigh In

KPTI has been the topic of a number of analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Royal Bank Of Canada reduced their target price on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, November 4th. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a report on Thursday, February 5th. They set an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Finally, The Goldman Sachs Group set a $12.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $14.83.

Karyopharm Therapeutics Stock Up 0.6%

Shares of KPTI opened at $9.41 on Friday. The business’s fifty day moving average is $7.59 and its 200 day moving average is $6.62. Karyopharm Therapeutics has a 12-month low of $3.51 and a 12-month high of $10.99. The stock has a market cap of $172.58 million, a P/E ratio of -0.57 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.03. The business had revenue of $34.08 million for the quarter, compared to analyst estimates of $33.16 million. On average, analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth approximately $163,000. Trexquant Investment LP purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at $307,000. ADAR1 Capital Management LLC lifted its stake in Karyopharm Therapeutics by 100.0% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,000 shares of the company’s stock valued at $368,000 after acquiring an additional 25,000 shares in the last quarter. State Street Corp lifted its stake in Karyopharm Therapeutics by 27.2% during the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after acquiring an additional 12,600 shares in the last quarter. Finally, Ikarian Capital LLC boosted its holdings in Karyopharm Therapeutics by 1,897.9% during the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after acquiring an additional 517,297 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.